Savara Inc. (SVRA)
NasdaqGS · USD · Healthcare · Biotechnology
$4.52 (+7.11%) as of
Key statistics
- Market cap
- 928.68M
- Forward P/E
- -12.32
- EPS (TTM)
- -0.5800
- Dividend yield
- 0.00%
- 52-week range
- 3.8600 – 7.0050
- Beta
- 0.20
- Profit margin
- 0.00%
- Analyst target
- $11.06
- Volume
- 3.44M
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Yardley, PA, United States
- Employees
- 70
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.